1 option
Pharmacoeconomic review report : (Eli Lilly Canada Inc.). Baricitinib (Olumiant) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Chemotherapy.
- COVID-19.
- Physical Description:
- 1 online resource : illustrations
- Edition:
- Version: final.
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2019.
- Summary:
- The objective of the current review is to perform a systematic review of the beneficial and harmful effects of baricitinib 2 mg orally once daily in combination with methotrexate(MTX) (or as monotherapy in cases of intolerance to MTX) for the treatment of adult patients with moderate-to-severe rheumatoid arthritis who have responded inadequately to one or more disease-modifying antirheumatic drugs.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.